DeepMatter announced on Thursday that it has been selected as a partner for the University of Leeds following a £1.4M EPSRC investment they received to develop automated precision manufacturing approaches in collaboration with the University of Sheffield, AstraZeneca, Somaserve and Samsung.
DeepMatter said it will provide its DigitalGlassware platform, a cloud-based platform that allows chemists to share data in real-time and develop digitally-enabled scale-up advanced nanoparticle products.
The AIM-listed company said the product was selected due to its “strong fit for early-stage chemical development.”
Empfohlener Broker
Multi Asset Platform
The company will also provide its sensor package, DeviceX, and a hardware device to interface with the continuous platforms at the University of Leeds.
Mark Warne, CEO of DeepMatter Group, commented: “We are delighted to be partnering with both the key opinion leaders at the University of Leeds and University of Sheffield, as well as large pharma companies.
“Our DigitalGlassware platform will be used to provide a unique perspective on the data helping with both discovery and productivity gains for chemical reactions forming nanoparticles – an essential component in delivering effective mRNA vaccines.”
DeepMatter shares are currently trading at 1.82p, up 1.11%
Should you invest in DeepMatter shares?
DeepMatter shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are DeepMatter shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies